December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 4 5 Next >
News headline image
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Provides Update on Clinical and Financial Status
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite’s CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Can-Fite Reports H1 2025 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
News headline image
Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.